secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001628280-23-017579
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Therapeutics reports Q1 2023 net loss of $5.6M; VYN201 Phase 1b data expected Q3 2023
--------------------------------------------------------------------------------

- Q1 2023 GAAP net loss $5.6M vs net income $4.7M in Q1 2022; loss from continuing ops improved to $5.6M from $8.7M.
- Topline 16-week data for all three cohorts of VYN201 Phase 1b trial in vitiligo expected in Q3 2023.
- Lead development candidate selected for VYN202 oral BD2-selective BET inhibitor; IND filing targeted by year-end 2023.
- Positive safety and PK data from VYN201 Phase 1a; no serious adverse events or dose adjustments.
- Preclinical data for inhaled VYN201 in IPF model showed anti-inflammatory and anti-fibrotic effects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000162828023017579/0001628280-23-017579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000162828023017579/mnlo-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-017579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer